Risk factor
Very poor trading liquidity
Profitability factor
Greatly undervalued vs peers
About
MPH Health Care AG is a German-based investment firm with a primary focus on the healthcare sector. The company's portfolio includes the production and distribution of medicinal products designed to treat serious illnesses like cancer, HIV, and various other chronic conditions. Beyond pharmaceuticals, it also delivers medical aesthetic treatments, develops and markets a diverse array of pharmaceutical and medical items, and furnishes related services and specialized medical devices for use in aesthetic surgery and cosmetic dermatology. Furthermore, its operations extend to supplying cytostatic solutions and involvement in real estate ventures. Established in Berlin in 2008, the company adopted its current name, MPH Health Care AG, in 2017, having previously been known as MPH Mittelständische Pharma Holding AG. It functions as a subsidiary of Magnum AG.
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD
Target Price
The average target price of 93M1.DE is 40.0 and suggests 41.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i